Page last updated: 2024-08-23

phenyl acetate and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

phenyl acetate has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (25.00)29.6817
2010's2 (50.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Fan, L; Hu, A; Li, F; Liang, J; Liu, C; Mu, CF; Xiong, Y1
Bandyopadhyay, S; Cheng, JX; Li, J; Oh, ST; Traer, E; Tyner, JW; Zhou, A1
Nilsson, A; Salamon, D; Stenke, L; Wallvik, J; Yektaei-Karin, E; Zovko, A1
Ikegawa, T; Koyabu, N; Morimoto, S; Naito, M; Ohtani, H; Sawada, Y; Shoyama, Y; Tsuruo, T; Ushigome, F1

Other Studies

4 other study(ies) available for phenyl acetate and Leukemia, Myelogenous, Chronic, BCR-ABL Positive

ArticleYear
Dual oligopeptides modification mediates arsenic trioxide containing nanoparticles to eliminate primitive chronic myeloid leukemia cells inside bone marrow niches.
    International journal of pharmaceutics, 2020, Apr-15, Volume: 579

    Topics: Acetates; Animals; Arsenic Trioxide; Bone Marrow; Cell Proliferation; Cells, Cultured; Drug Delivery Systems; Female; Human Umbilical Vein Endothelial Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Nanoparticles; Neoplastic Stem Cells; Oligopeptides; Organometallic Compounds; Polymers; Tumor Stem Cell Assay

2020
Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
    PloS one, 2017, Volume: 12, Issue:7

    Topics: Acetamides; Acetates; Animals; Apoptosis; Cell Proliferation; Cholesterol; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Esterification; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Mice; Mutation; Protein Kinase Inhibitors; Sulfonamides; Sulfonic Acids; Xenograft Model Antitumor Assays

2017
Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis.
    Oncology reports, 2018, Volume: 40, Issue:2

    Topics: Acetates; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclopropanes; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukotriene Antagonists; Protein Kinase Inhibitors; Quinolines; Receptors, Leukotriene; Signal Transduction; Sulfides

2018
Inhibition of P-glycoprotein by orange juice components, polymethoxyflavones in adriamycin-resistant human myelogenous leukemia (K562/ADM) cells.
    Cancer letters, 2000, Nov-10, Volume: 160, Issue:1

    Topics: Acetates; ATP Binding Cassette Transporter, Subfamily B; Beverages; Blotting, Western; Citrus; Cyclosporine; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flavones; Flavonoids; Furocoumarins; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Plant Extracts; Tritium; Verapamil; Vincristine

2000